Dupilumab in patients with diffuse type 2 CRSwNP had beneficial changes in nasal passage microbiota but did not alter gastrointestinal microbiota.

“The nasal passages have a normal physiologic response to different levels of activity,” says Michael Yong, MD, board-certified otolaryngologist and fellowship-trained neurorhinologist at ...